Apollo endosurgery announces publication in the lancet of landmark study for the endoscopic sleeve gastroplasty procedure

Publication of merit study follows fda market authorization of apollo esg™ austin, tx / accesswire / july 29, 2022 / apollo endosurgery, inc. ("apollo") (nasdaq:apen), a global leader in minimally invasive medical devices for gastrointestinal and bariatric procedures, announced today the electronic publication of the landmark multi-center esg randomized interventional trial (merit) study in the lancet.(1) the merit study is a multi-center, prospective randomized clinical trial evaluating the safety and effectiveness of the endoscopic sleeve gastroplasty (esg) procedure, a minimally invasive, endoscopic weight loss procedure performed with apollo's endosurgery's overstitch® endoscopic suturing system.in the study, patients with body mass index (bmi) ≥30 and ≤40 kg/m² were randomized to treatment with esg and lifestyle modification or to a control group which involved lifestyle modification alone.
APEN Ratings Summary
APEN Quant Ranking